We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mutation Identified as Genetic Marker for Multiple Sclerosis

By LabMedica International staff writers
Posted on 16 Mar 2015
A mutation in the serine-threonine kinase 11 (STK11) gene, which encodes the enzyme liver kinase b1 (LKB1), was shown to be a risk factor for development of multiple sclerosis (MS).

STK11 gene encodes a member of the serine/threonine kinase family and thereby regulates cell polarity while functioning as a tumor suppressor. More...
Mutations in this gene have been associated with Peutz-Jeghers syndrome, an autosomal dominant disorder characterized by the growth of polyps in the gastrointestinal tract, pigmented macules on the skin and mouth, and other cancerous growths.

A serendipitous conversation led investigators at the University of Illinois at Chicago (USA) to apply advanced DNA sequencing tools to study a family whose female members had a high prevalence for both MS and Peutz-Jeghers syndrome.

Sequence analysis of total DNA from one sister from a family with five daughters suffering from MS identified a single-nucleotide polymorphism (SNP) within STK11 intron 5. This SNP (rs9282860) was then identified by Life Technologies (Carlsbad, CA, USA;) TaqMan polymerase chain reaction (PCR) assays in DNA samples available from two other siblings. Further screening was carried out on samples from 654 relapsing-remitting MS patients, 100 primary progressive MS patients, and 661 controls. Results revealed that the STK11-SNP had increased frequency in all female MS patients versus controls.

The STK11-SNP was not associated with disease duration or onset; however, it was significantly associated with reduced severity. In vitro studies showed that peripheral blood mononuclear cells from members of the family were more sensitive to the mitochondrial inhibitor metformin than cells from MS patients with the non-mutated STK11 allele. Thus, the increased association of SNP rs9282860 in women with MS defined this variant as a genetic risk factor.

"The variant occurs almost twice as often among women with MS as in women without the disease, making it one of the strongest genetic risk factors for MS discovered to date," said senior author Dr. Douglas Feinstein, professor of anesthesiology at the University of Illinois at Chicago. "The STK11 SNP is present in about 7% of the general population. But because far fewer people develop MS, other genetic or non-genetic factors must play a role in the development of the disease."

The report was published in the February 18, 2015, online edition of the journal ASN NEURO.

Related Links:

University of Illinois at Chicago
Life Technologies 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.